Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that data from its
recently-completed Fampridine-SR Phase 3 trial (MS-F204) will be presented
during a poster session at the World Congress in Treatment and Research in MS
Meeting (ACTRIMS, ECTRIMS and LACTRIMS) on Saturday, September 20, 2008 in
Montreal, Canada. The Company previously announced top-line data from MS-F204 on
June 2, 2008, and the poster will provide additional data from that clinical
trial.
The poster, "Sustained-Release Fampridine Consistently Improves
Walking Speed And Leg Strength In Multiple Sclerosis: A Phase 3 Trial," will be
presented by Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at
the University of Rochester, from 10:00 to 10:30 a.m. ET. Viewing hours will be
from 8:30 a.m. to 12:00 p.m. ET in the Viger Foyer outside Room 517.
About Fampridine-SR Fampridine-SR is a sustained-release
tablet formulation of the investigational drug fampridine (4-aminopyridine or
4-AP). In laboratory studies, fampridine has been found to improve impulse
conduction in nerve fibers in which the insulating layer, called myelin, has
been damaged. Fampridine-SR recently completed a second Phase 3 clinical trial
to evaluate its safety and efficacy in improving walking ability in people with
MS.
About Acorda Therapeutics Acorda Therapeutics is a
biotechnology company developing therapies for spinal cord injury, multiple
sclerosis and related nervous system disorders. The Company's marketed products
include
Zanaflex
Capsules® (tizanidine hydrochloride), a short-acting drug for the management of
spasticity. Acorda's lead clinical product, Fampridine-SR, recently completed a
second Phase 3 clinical trial to evaluate its safety and efficacy in improving
walking ability in people with MS. The Company's pipeline includes a number of
products in development for the treatment, regeneration and repair of the spinal
cord and brain.
http://www.acorda.comForward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, regarding management's expectations,
beliefs, goals, plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause actual
results to differ materially, including delays in obtaining or failure to obtain
FDA approval of Fampridine-SR, the risk of unfavorable results from future
studies of Fampridine-SR, Acorda Therapeutics' ability to successfully market
and sell Fampridine-SR, if approved, and Zanaflex Capsules, competition, failure
to protect its intellectual property or to defend against the intellectual
property claims of others, the ability to obtain additional financing to support
Acorda Therapeutics' operations, and unfavorable results from its preclinical
programs. These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission. Acorda
Therapeutics may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue reliance on
these statements. Acorda Therapeutics disclaims any intent or obligation to
update any forward-looking statements as a result of developments occurring
after the date of this press release.
Acorda Therapeutics
